2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4044 Peri-infusion EASIX trajectories and CRS/ icans after BCMA-directed CAR T-cell therapy for multiple myeloma

Utkarsh Goel, MD, Catalin Dragomirescu2, Mohamed Hashem3, Diana Basali, MD4, Roy Chedid, MD5, Louis Samuel Williams, MD6, Sandra Mazzoni, DO7, Shahzad Raza, MD8, Jack Khouri, MD9
1 Mayo Clinic, Rochester, Minnesota, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 University of Cincinnati, Cincinnati, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States

Background

Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS) can be predicted using Endothelial Activation and Stress Index (EASIX) scores, which include routine laboratory parameters and inflammatory markers. Existing studies predicting CRS/ICANS in multiple myeloma (MM) have typically considered assessments at a single time point (e.g., pre-apheresis or pre-infusion). However, the treatment path from apheresis to CAR-T infusion is complicated and often involves bridging therapy (BT), which can alter disease burden and inflammatory markers, highlighting the need for a dynamic risk stratification approach.

Methods

We included patients with MM treated with standard-of-care idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) at our institution from Aug 1, 2021, and Jan 31, 2024. We calculated EASIX [lactate dehydrogenase (LDH) (U/L) x creatinine (Cr) (mg/dL) / platelet count (109/L)], modified EASIX [mEASIX: LDH x CRP / platelet count], simplified EASIX [sEASIX: LDH / platelet count], and CAR-HEMATOTOX (CAR-HT, ≥2 considered high) serially at six peri-infusion timepoints: apheresis, LD, pre-infusion (day 0), and days +1, +2, +3 post-infusion.

We used logistic regression to assess relations between respective scores at each timepoint and occurrence of CRS/ICANS. To reduce skewness, we log2 transformed continuous EASIX scores (ORs thus represent changes associated with doubling of the score). Next, we evaluated serial log2 EASIX/mEASIX/sEASIX across the six peri-infusion timepoints and performed exploratory trajectory clustering to identify distinct peri-infusion patterns.

Results

A total of 103 patients (58 cilta-cel, 45 ide-cel) with a median of 5 prior lines (range 4-14) were included. Ninety percent had triple-class refractory disease; 22% had extramedullary disease prior to infusion; 62% received BT (ORR 17% with BT). Overall, 76% patients developed any grade CRS (27% ≥ grade 2, 7% ≥ grade 3) and 25% developed any grade ICANS (9% ≥ grade 2, 5% ≥ grade 3).

All scores showed limited discrimination for any grade CRS at all peri-infusion timepoints. In contrast, several scores demonstrated a strong association with ≥ grade 2 CRS and ICANS. Pre-apheresis EASIX (OR 1.4 per doubling of score; 95% CI 1.1-1.9; AUC 0.68) and sEASIX (OR 1.5; 95% CI 1.1-2.1; AUC 0.69) were associated with ≥ grade 2 CRS, with consistent associations through later timepoints (EASIX AUCs 0.71-0.73 from pre-LD through day +3; sEASIX AUCs 0.71-0.73). Pre-apheresis EASIX (OR 1.3; 95% CI 1.04-1.7; AUC 0.68) and sEASIX (OR 1.4; 95% CI 1.04-1.9; AUC 0.64) also predicted any-grade ICANS. CAR-HT showed association with ICANS at later timepoints (e.g., day +3, high CAR-HT OR 4.4; 95% CI 1.4-13.8; AUC 0.64).

We then assessed serial EASIX trajectories among patients with complete data at all timepoints (n=96). Median log2(EASIX) increased modestly from 0.12 at apheresis to 0.69 pre-infusion. Values then remained relatively stable, ranging from 0.60 to 0.66 across days +1 to +3. Stratification by response to BT did not reveal major differences in EASIX trajectories.

We identified three trajectory groups that were already separated at apheresis and remained distinct across the peri-infusion period: persistent low EASIX (n=56; median log2[EASIX] -0.45; IQR -0.76 to -0.08), intermediate EASIX (n=30; median log2[EASIX] 1.01; IQR 0.44-1.60), and persistent high EASIX (n=10; median log2[EASIX] 4.11; IQR 1.18-4.67). Parallel exploratory analyses using mEASIX and sEASIX showed similar patterns. Any-grade CRS rates were similar across persistent low, intermediate, and persistent high EASIX groups (73%, 73%, and 80%). Clinically meaningful toxicity increased stepwise across groups, including grade ≥2 CRS (16%, 30%, 60%), any-grade ICANS (9%, 37%, 60%), and grade ≥2 ICANS (0%, 10%, 40%). The clusters also predicted PFS, OS. Median PFS (95% CI): NR/9.8 (8.2-NR)/1.0 (0.5-NR); OS: 26.7 (26.3-NR)/NR (13.8-NR)/1.8 (0.5-NR) months in low/intermediate/high clusters.

Conclusion

EASIX-based risk profiles were apparent as early as apheresis and were maintained through infusion and the early post-infusion period. These findings support early toxicity risk stratification beginning at apheresis, with serial assessments helping confirm the stability of these risk profiles across the peri-CAR-T treatment course. These results may help inform toxicity prophylaxis approaches and feasibility of outpatient administration.

Utkarsh Goel, MD: No relevant conflicts of interest to declare.